Tarsus Pharmaceuticals, Inc. (TARS) operating KPIs
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/301% below fair value
$74.85+0.65 (+0.88%)
Close on Oct 30, 2026Market cap $3.28BP/E –Yield 0.00%
KPIs
Operating metrics that drive Tarsus Pharmaceuticals's business
| Rentable area (sq ft) | Q2 26 | Q1 26 | Q3 25 | Q4 24 |
|---|---|---|---|---|
| Rentable area | 59,626 | 98,807 | 98,807 | 59,626 |
Counts and sizes Tarsus Pharmaceuticals tags in the notes of its 10-K and 10-Q filings (XBRL), as of the end of each quarter. Breakdowns follow the company's own labels; at most 15 are shown per metric. A fuller KPI sheet built from earnings releases and presentations is on the way. See how companies compare on these metrics.